Which outcome measures should be used in rheumatoid arthritis clinical trials?.

Measuring outcome in rheumatoid arthritis--which measures are suitable for routine clinical use?

adult SLE patients was noted between the presence or levels of antibodies to hsp90 and the presence or levels of rheumatoid factor. It is thus clear that the disease-specific occurrence of autoantibodies to hsp90 in adult SLE patients [1] and MRL/lpr mice [2] cannot be accounted for by the presence of RF. In our studies, we did not examine in detail the immune response to human hsp65. It would ...

Outcome measures to be used in clinical trials in systemic lupus erythematosus.

The optimal outcome measures to be employed in clinical trials of systemic lupus erythematosus (SLE) have yet to be determined. Useful instruments should assess disease outcome in terms of all organ system involvement, as well as measures important to the patient. This article reviews those outcome measures that have been utilized in cohort studies in SLE, as well as their limited use in random...

OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction.

Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?

The information used by rheumatologists when delivering care to patients with rheumatoid arthritis (RA) is derived mainly from two sources: randomised controlled clinical trials and experience in clinical care. However, these two sources differ significantly because (a) the extensive inclusion and exclusion criteria result in clinical trial participants being recruited from only a minority of p...

Which treatment option should be used?